Paul F. Hollenberg - Publications

Affiliations: 
University of Michigan, Ann Arbor, Ann Arbor, MI 
Area:
Pharmacology, Biochemistry

142 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Zhang H, Yokom AL, Cheng S, Su M, Hollenberg PF, Southworth DR, Osawa Y. The full-length cytochrome P450 enzyme CYP102A1 dimerizes at its reductase domains and has flexible heme domains for efficient catalysis. The Journal of Biological Chemistry. PMID 29618513 DOI: 10.1074/Jbc.Ra117.000600  0.64
2018 Lin HL, Zhang H, Hollenberg PF. Formation of Both Heme and Apoprotein Adducts Contributes to the Mechanism-Based Inactivation of Human CYP2J2 by 17α-Ethynylestradiol. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 29602797 DOI: 10.1124/Dmd.118.080903  0.64
2017 Lin HL, Zhang H, Walker VJ, D'Agostino J, Hollenberg PF. Heme Modification Contributes to the Mechanism-Based Inactivation of Human Cytochrome P450 2J2 by Two Terminal Acetylenic Compounds. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 28698302 DOI: 10.1124/Dmd.117.075846  0.64
2016 Lin HL, Zhang H, Kenaan C, Hollenberg PF. Mutation of F206 and V367 to Alanine in Human Cytochrome P450 2B6: Effects on the Selectivity of Androgen Hydroxylation, Mechanism-based Inactivation, and Reversible Inhibition. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 27538916 DOI: 10.1124/Dmd.116.071662  0.76
2016 Zhang H, Lauver DA, Wang H, Sun D, Hollenberg PF, Chen YE, Osawa Y, Eitzman DT. Significant Improvement Of Antithrombotic Responses To Clopidogrel By Use Of A Novel Conjugate As Revealed In An Arterial Model Of Thrombosis. The Journal of Pharmacology and Experimental Therapeutics. PMID 27511819 DOI: 10.1124/Jpet.116.236034  0.64
2016 Snider NT, Walker VJ, Hollenberg PF. Assay of Endocannabinoid Oxidation by Cytochrome P450. Methods in Molecular Biology (Clifton, N.J.). 1412: 227-36. PMID 27245908 DOI: 10.1007/978-1-4939-3539-0_23  0.64
2016 Spolitak T, Hollenberg PF, Ballou DP. Oxidative hemoglobin reactions: Applications to drug metabolism. Archives of Biochemistry and Biophysics. PMID 27091316 DOI: 10.1016/J.Abb.2016.04.007  0.76
2016 Walker VJ, Griffin AP, Hammar DK, Hollenberg PF. Metabolism of Anandamide by Human Cytochrome P450 2J2 in the Reconstituted System and Human Intestinal Microsomes. The Journal of Pharmacology and Experimental Therapeutics. PMID 27000802 DOI: 10.1124/Jpet.116.232553  0.56
2015 D'Agostino J, Zhang H, Kenaan C, Hollenberg PF. Mechanism-Based Inactivation of Human Cytochrome P450 2B6 by Chlorpyrifos. Chemical Research in Toxicology. 28: 1484-95. PMID 26075493 DOI: 10.1021/Acs.Chemrestox.5B00156  1
2015 Calinski DM, Zhang H, Ludeman S, Dolan ME, Hollenberg PF. Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 43: 1084-90. PMID 25934575 DOI: 10.1124/Dmd.115.063628  1
2014 Sturla SJ, Hollenberg P. Systems toxicology: a special issue. Chemical Research in Toxicology. 27: 311. PMID 24635561 DOI: 10.1021/Tx500024U  1
2013 Lin HL, D'Agostino J, Kenaan C, Calinski D, Hollenberg PF. The effect of ritonavir on human CYP2B6 catalytic activity: heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavir. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 1813-24. PMID 23886699 DOI: 10.1124/Dmd.113.053108  1
2013 Yoshigae Y, Kent UM, Hollenberg PF. Role of the highly conserved threonine in cytochrome P450 2E1: prevention of H2O2-induced inactivation during electron transfer. Biochemistry. 52: 4636-47. PMID 23750736 DOI: 10.1021/Bi4004843  0.64
2013 Kenaan C, Zhang H, Hollenberg PF. High-throughput fluorescence assay for cytochrome P450 mechanism-based inactivators. Methods in Molecular Biology (Clifton, N.J.). 987: 61-9. PMID 23475667 DOI: 10.1007/978-1-62703-321-3_5  1
2013 Yoshigae Y, Sridar C, Kent UM, Hollenberg PF. The inactivation of human CYP2E1 by phenethyl isothiocyanate, a naturally occurring chemopreventive agent, and its oxidative bioactivation. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 858-69. PMID 23371965 DOI: 10.1124/Dmd.112.050609  0.76
2013 Zhang H, Lauver DA, Lucchesi BR, Hollenberg PF. Formation, reactivity, and antiplatelet activity of mixed disulfide conjugates of clopidogrel. Molecular Pharmacology. 83: 848-56. PMID 23348501 DOI: 10.1124/Mol.112.084392  0.64
2013 Zhang H, Gay SC, Shah M, Foroozesh M, Liu J, Osawa Y, Zhang Q, Stout CD, Halpert JR, Hollenberg PF. Potent mechanism-based inactivation of cytochrome P450 2B4 by 9-ethynylphenanthrene: Implications for allosteric modulation of cytochrome P450 catalysis Biochemistry. 52: 355-364. PMID 23276288 DOI: 10.1021/Bi301567Z  1
2013 Kenaan C, Shea EV, Lin HL, Zhang H, Pratt-Hyatt MJ, Hollenberg PF. Interactions between CYP2E1 and CYP2B4: effects on affinity for NADPH-cytochrome P450 reductase and substrate metabolism. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 101-10. PMID 23043184 DOI: 10.1124/Dmd.112.046094  1
2013 Sridar C, Hanna I, Hollenberg PF. Quantitation of UGT1A1 in human liver microsomes using stable isotope-labelled peptides and mass spectrometry based proteomic approaches. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 43: 336-45. PMID 22943130 DOI: 10.3109/00498254.2012.719089  0.76
2012 Lin HL, Kenaan C, Zhang H, Hollenberg PF. Reaction of human cytochrome P450 3A4 with peroxynitrite: nitrotyrosine formation on the proximal side impairs its interaction with NADPH-cytochrome P450 reductase. Chemical Research in Toxicology. 25: 2642-53. PMID 23016756 DOI: 10.1021/Tx3002753  1
2012 Sridar C, D'Agostino J, Hollenberg PF. Bioactivation of the cancer chemopreventive agent tamoxifen to quinone methides by cytochrome P4502B6 and identification of the modified residue on the apoprotein. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 2280-8. PMID 22942317 DOI: 10.1124/Dmd.112.047266  1
2012 Sridar C, Kenaan C, Hollenberg PF. Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 2256-66. PMID 22936314 DOI: 10.1124/Dmd.112.046979  1
2012 Amunugama HT, Zhang H, Hollenberg PF. Mechanism-based inactivation of cytochrome P450 2B6 by methadone through destruction of prosthetic heme. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 1765-70. PMID 22685215 DOI: 10.1124/dmd.112.045971  0.64
2012 Zhang H, Lau WC, Hollenberg PF. Formation of the thiol conjugates and active metabolite of clopidogrel by human liver microsomes. Molecular Pharmacology. 82: 302-9. PMID 22584220 DOI: 10.1124/Mol.112.079061  1
2012 Lin HL, Kenaan C, Hollenberg PF. Identification of the residue in human CYP3A4 that is covalently modified by bergamottin and the reactive intermediate that contributes to the grapefruit juice effect. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 998-1006. PMID 22344702 DOI: 10.1124/Dmd.112.044560  1
2011 Lin HL, Zhang H, Pratt-Hyatt MJ, Hollenberg PF. Thr302 is the site for the covalent modification of human cytochrome P450 2B6 leading to mechanism-based inactivation by tert-butylphenylacetylene. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 2431-9. PMID 21930824 DOI: 10.1124/Dmd.111.042176  1
2011 Zhang H, Amunugama H, Ney S, Cooper N, Hollenberg PF. Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of heme. Molecular Pharmacology. 80: 839-47. PMID 21862689 DOI: 10.1124/Mol.111.073783  0.64
2011 Zhang H, Sridar C, Kenaan C, Amunugama H, Ballou DP, Hollenberg PF. Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: A charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome P450-reductase complex Journal of Pharmacology and Experimental Therapeutics. 338: 803-809. PMID 21659470 DOI: 10.1124/Jpet.111.183111  1
2011 Gay SC, Zhang H, Wilderman PR, Roberts AG, Liu T, Li S, Lin HL, Zhang Q, Woods VL, Stout CD, Hollenberg PF, Halpert JR. Structural analysis of mammalian cytochrome P450 2B4 covalently bound to the mechanism-based inactivator tert-butylphenylacetylene: insight into partial enzymatic activity. Biochemistry. 50: 4903-11. PMID 21510666 DOI: 10.1021/Bi200482G  1
2011 Kenaan C, Zhang H, Shea EV, Hollenberg PF. Uncovering the role of hydrophobic residues in cytochrome P450-cytochrome P450 reductase interactions. Biochemistry. 50: 3957-67. PMID 21462923 DOI: 10.1021/Bi1020748  1
2011 Sridar C, Snider NT, Hollenberg PF. Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 782-8. PMID 21289075 DOI: 10.1124/Dmd.110.036707  1
2011 Lin HL, Zhang H, Medower C, Hollenberg PF, Johnson WW. Inactivation of cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a thiophene-containing anticancer drug. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 345-50. PMID 21068193 DOI: 10.1124/Dmd.110.034074  0.64
2011 Zhang H, Lin HL, Kenaan C, Hollenberg PF. Targeting of the highly conserved threonine 302 residue of cytochromes P450 2B family during mechanism-based inactivation by aryl acetylenes. Archives of Biochemistry and Biophysics. 507: 135-43. PMID 20836985 DOI: 10.1016/J.Abb.2010.09.006  1
2010 Kenaan C, Zhang H, Hollenberg PF. A quantitative high-throughput 96-well plate fluorescence assay for mechanism-based inactivators of cytochromes P450 exemplified using CYP2B6. Nature Protocols. 5: 1652-8. PMID 20885377 DOI: 10.1038/Nprot.2010.125  1
2010 Pratt-Hyatt M, Lin HL, Hollenberg PF. Mechanism-based inactivation of human CYP2E1 by diethyldithocarbamate. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 38: 2286-92. PMID 20826547 DOI: 10.1124/Dmd.110.034710  0.64
2010 Pratt-Hyatt M, Zhang H, Snider NT, Hollenberg PF. Effects of a commonly occurring genetic polymorphism of human CYP3A4 (I118V) on the metabolism of anandamide. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 38: 2075-82. PMID 20702771 DOI: 10.1124/Dmd.110.033712  1
2010 Lin HL, Zhang H, Jushchyshyn M, Hollenberg PF. Covalent modification of Thr302 in cytochrome P450 2B1 by the mechanism-based inactivator 4-tert-butylphenylacetylene. The Journal of Pharmacology and Experimental Therapeutics. 333: 663-9. PMID 20200115 DOI: 10.1124/Jpet.109.164350  0.64
2010 Jang HH, Jamakhandi AP, Sullivan SZ, Yun CH, Hollenberg PF, Miller GP. Beta sheet 2-alpha helix C loop of cytochrome P450 reductase serves as a docking site for redox partners. Biochimica Et Biophysica Acta. 1804: 1285-93. PMID 20152939 DOI: 10.1016/J.Bbapap.2010.02.003  1
2010 Snider NT, Walker VJ, Hollenberg PF. Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications. Pharmacological Reviews. 62: 136-54. PMID 20133390 DOI: 10.1124/Pr.109.001081  1
2010 Bumpus NN, Hollenberg PF. Cross-linking of human cytochrome P450 2B6 to NADPH-cytochrome P450 reductase: Identification of a potential site of interaction. Journal of Inorganic Biochemistry. 104: 485-8. PMID 20096935 DOI: 10.1016/J.Jinorgbio.2009.12.017  1
2010 Mak PJ, Zhang H, Hollenberg PF, Kincaid JR. Defining the structural consequences of mechanism-based inactivation of mammalian cytochrome P450 2B4 using resonance Raman spectroscopy. Journal of the American Chemical Society. 132: 1494-5. PMID 20078059 DOI: 10.1021/Ja910276S  1
2010 Hanada S, Snider NT, Brunt EM, Hollenberg PF, Omary MB. Gender dimorphic formation of mouse Mallory-Denk bodies and the role of xenobiotic metabolism and oxidative stress. Gastroenterology. 138: 1607-17. PMID 20064513 DOI: 10.1053/J.Gastro.2009.12.055  1
2010 Mak PJ, Kincaid JR, Denisov IG, Sligar SG, Zhang H, Hollenberg PF. Resonance Raman studies on mammalian cytochromes P450 Aip Conference Proceedings. 1267: 890-891. DOI: 10.1063/1.3482873  1
2009 Zhang H, Lin HL, Walker VJ, Hamdane D, Hollenberg PF. tert-Butylphenylacetylene is a potent mechanism-based inactivator of cytochrome P450 2B4: inhibition of cytochrome P450 catalysis by steric hindrance. Molecular Pharmacology. 76: 1011-8. PMID 19720728 DOI: 10.1124/Mol.109.059808  0.64
2009 Lin HL, Zhang H, Noon KR, Hollenberg PF. Mechanism-based inactivation of CYP2B1 and its F-helix mutant by two tert-butyl acetylenic compounds: covalent modification of prosthetic heme versus apoprotein. The Journal of Pharmacology and Experimental Therapeutics. 331: 392-403. PMID 19700628 DOI: 10.1124/Jpet.109.158782  0.64
2009 Zhang H, Kenaan C, Hamdane D, Hoa GH, Hollenberg PF. Effect of conformational dynamics on substrate recognition and specificity as probed by the introduction of a de novo disulfide bond into cytochrome P450 2B1. The Journal of Biological Chemistry. 284: 25678-86. PMID 19605359 DOI: 10.1074/Jbc.M109.032748  1
2009 Sheng X, Zhang H, Im SC, Horner JH, Waskell L, Hollenberg PF, Newcomb M. Kinetics of oxidation of benzphetamine by compounds I of cytochrome P450 2B4 and its mutants Journal of the American Chemical Society. 131: 2971-2976. PMID 19209859 DOI: 10.1021/Ja808982G  1
2009 Sheng X, Zhang H, Hollenberg PF, Newcomb M. Kinetic isotope effects in hydroxylation reactions effected by cytochrome P450 compounds I implicate multiple electrophilic oxidants for P450-catalyzed oxidations. Biochemistry. 48: 1620-7. PMID 19182902 DOI: 10.1021/Bi802279D  0.64
2009 Snider NT, Nast JA, Tesmer LA, Hollenberg PF. A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist. Molecular Pharmacology. 75: 965-72. PMID 19171674 DOI: 10.1124/Mol.108.053439  1
2009 Lin HL, Zhang H, Hollenberg PF. Metabolic activation of mifepristone [RU486; 17beta-hydroxy-11beta-(4-dimethylaminophenyl)-17alpha-(1-propynyl)-estra-4,9-dien-3-one] by mammalian cytochromes P450 and the mechanism-based inactivation of human CYP2B6. The Journal of Pharmacology and Experimental Therapeutics. 329: 26-37. PMID 19168709 DOI: 10.1124/Jpet.108.148536  0.64
2009 Shebley M, Kent UM, Ballou DP, Hollenberg PF. Mechanistic analysis of the inactivation of cytochrome P450 2B6 by phencyclidine: Effects on substrate binding, electron transfer, and uncoupling Drug Metabolism and Disposition. 37: 745-752. PMID 19144770 DOI: 10.1124/Dmd.108.024661  1
2008 Kent UM, Sridar C, Spahlinger G, Hollenberg PF. Modification of serine 360 by a reactive intermediate of 17-alpha-ethynylestradiol results in mechanism-based inactivation of cytochrome P450s 2B1 and 2B6. Chemical Research in Toxicology. 21: 1956-63. PMID 18729327 DOI: 10.1021/Tx800138V  1
2008 Snider NT, Sikora MJ, Sridar C, Feuerstein TJ, Rae JM, Hollenberg PF. The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6 Journal of Pharmacology and Experimental Therapeutics. 327: 538-545. PMID 18698000 DOI: 10.1124/Jpet.108.141796  1
2008 Sridar C, Kent UM, Noon K, McCall A, Alworth B, Foroozesh M, Hollenberg PF. Differential inhibition of cytochromes P450 3A4 and 3A5 by the newly synthesized coumarin derivatives 7-coumarin propargyl ether and 7-(4-trifluoromethyl)coumarin propargyl ether. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 2234-43. PMID 18653744 DOI: 10.1124/Dmd.108.021493  0.76
2008 Bumpus NN, Hollenberg PF. Investigation of the mechanisms underlying the differential effects of the K262R mutation of P450 2B6 on catalytic activity. Molecular Pharmacology. 74: 990-9. PMID 18621926 DOI: 10.1124/Mol.108.048637  1
2008 Hollenberg PF, Kent UM, Bumpus NN. Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications. Chemical Research in Toxicology. 21: 189-205. PMID 18052110 DOI: 10.1021/Tx7002504  1
2007 Lin HL, Myshkin E, Waskell L, Hollenberg PF. Peroxynitrite inactivation of human cytochrome P450s 2B6 and 2E1: Heme modification and site-specific nitrotyrosine formation Chemical Research in Toxicology. 20: 1612-1622. PMID 17907788 DOI: 10.1021/Tx700220E  1
2007 von Weymarn LB, Chun JA, Knudsen GA, Hollenberg PF. Effects of eleven isothiocyanates on P450 2A6- and 2A13-catalyzed coumarin 7-hydroxylation. Chemical Research in Toxicology. 20: 1252-9. PMID 17672516 DOI: 10.1021/Tx700078V  1
2007 Shebley M, Hollenberg PF. Mutation of a single residue (K262R) in P450 2B6 leads to loss of mechanism-based inactivation by phencyclidine. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 35: 1365-71. PMID 17460030 DOI: 10.1124/Dmd.107.014985  1
2007 Newcomb M, Lansakara-P DS, Kim HY, Chandrasena RE, Lippard SJ, Beauvais LG, Murray LJ, Izzo V, Hollenberg PF, Coon MJ. Products from enzyme-catalyzed oxidations of norcarenes. The Journal of Organic Chemistry. 72: 1128-33. PMID 17288367 DOI: 10.1021/Jo061865J  1
2007 Newcomb M, Chandrasena RE, Lansakara-P DS, Kim HY, Lippard SJ, Beauvais LG, Murray LJ, Izzo V, Hollenberg PF, Coon MJ. Desaturase reactions complicate the use of norcarane as a mechanistic probe. Unraveling the mixture of twenty-plus products formed in enzyme-catalyzed oxidations of norcarane. The Journal of Organic Chemistry. 72: 1121-7. PMID 17288366 DOI: 10.1021/Jo061864R  1
2007 Mensah-Osman EJ, Thomas DG, Tabb MM, Larios JM, Hughes DP, Giordano TJ, Lizyness ML, Rae JM, Blumberg B, Hollenberg PF, Baker LH. Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 109: 957-65. PMID 17279585 DOI: 10.1002/Cncr.22479  1
2007 Snider NT, Kornilov AM, Kent UM, Hollenberg PF. Anandamide metabolism by human liver and kidney microsomal cytochrome p450 enzymes to form hydroxyeicosatetraenoic and epoxyeicosatrienoic acid ethanolamides. The Journal of Pharmacology and Experimental Therapeutics. 321: 590-7. PMID 17272674 DOI: 10.1124/Jpet.107.119321  1
2007 Lin HL, Hollenberg PF. The inactivation of cytochrome P450 3A5 by 17alpha-ethynylestradiol is cytochrome b5-dependent: metabolic activation of the ethynyl moiety leads to the formation of glutathione conjugates, a heme adduct, and covalent binding to the apoprotein. The Journal of Pharmacology and Experimental Therapeutics. 321: 276-87. PMID 17251390 DOI: 10.1124/Jpet.106.117861  0.64
2006 Kobayashi Y, Sridar C, Kent UM, Puppali SG, Rimoldi JM, Zhang H, Waskell L, Hollenberg PF. Structure-activity relationship and elucidation of the determinant factor(s) responsible for the mechanism-based inactivation of cytochrome P450 2B6 by substituted phenyl diaziridines Drug Metabolism and Disposition. 34: 2102-2110. PMID 16997911 DOI: 10.1124/Dmd.106.011452  1
2006 Sridar C, Kobayashi Y, Brevig H, Kent UM, Puppali SG, Rimoldi JM, Hollenberg PF. Synthesis of substituted phenyl diaziridines and characterization as mechanism-based inactivators of human cytochrome P450 2B6. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 1849-55. PMID 16882766 DOI: 10.1124/Dmd.106.010082  1
2006 Kent UM, Lin HL, Noon KR, Harris DL, Hollenberg PF. Metabolism of bergamottin by cytochromes P450 2B6 and 3A5. The Journal of Pharmacology and Experimental Therapeutics. 318: 992-1005. PMID 16785317 DOI: 10.1124/Jpet.105.099887  0.64
2006 Jushchyshyn MI, Wahlstrom JL, Hollenberg PF, Wienkers LC. Mechanism of inactivation of human cytochrome P450 2B6 by phencyclidine. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 1523-9. PMID 16782764 DOI: 10.1124/Dmd.106.010579  1
2006 Bumpus NN, Kent UM, Hollenberg PF. Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms. The Journal of Pharmacology and Experimental Therapeutics. 318: 345-51. PMID 16611850 DOI: 10.1124/Jpet.106.102525  1
2006 Kent UM, Lin HL, Mills DE, Regal KA, Hollenberg PF. Identification of 17-alpha-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6. Chemical Research in Toxicology. 19: 279-87. PMID 16485904 DOI: 10.1021/Tx050256O  1
2006 von Weymarn LB, Chun JA, Hollenberg PF. Effects of benzyl and phenethyl isothiocyanate on P450s 2A6 and 2A13: potential for chemoprevention in smokers. Carcinogenesis. 27: 782-90. PMID 16364922 DOI: 10.1093/Carcin/Bgi301  1
2006 Shebley M, Jushchyshyn MI, Hollenberg PF. Selective pathways for the metabolism of phencyclidine by cytochrome p450 2b enzymes: identification of electrophilic metabolites, glutathione, and N-acetyl cysteine adducts. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 375-83. PMID 16326815 DOI: 10.1124/Dmd.105.007047  1
2006 Newcomb M, Shen R, Lu Y, Coon MJ, Hollenberg PF, Kopp DA, Lippard SJ. Evaluation of Norcarane as a Probe for Radicals in Cytochrome P450- and Soluble Methane Monooxygenase-Catalyzed Hydroxylation Reactions [J. Am. Chem. Soc.2002,124, 6879−6886]. Journal of the American Chemical Society. 128: 1394-1394. DOI: 10.1021/Ja0599216  0.48
2005 Morishima Y, Peng HM, Lin HL, Hollenberg PF, Sunahara RK, Osawa Y, Pratt WB. Regulation of cytochrome P450 2E1 by heat shock protein 90-dependent stabilization and CHIP-dependent proteasomal degradation. Biochemistry. 44: 16333-40. PMID 16331994 DOI: 10.1021/Bi0515570  1
2005 Sridar C, Harleton E, Hollenberg PF. Roles of the threonine 407, aspartic acid 417, and threonine 419 residues in P450 2B1 in metabolism. Biochemical and Biophysical Research Communications. 338: 386-93. PMID 16157292 DOI: 10.1016/J.Bbrc.2005.08.192  0.76
2005 Lin HL, Zhang H, Waskell L, Hollenberg PF. The highly conserved Glu149 and Tyr190 residues contribute to peroxynitrite-mediated nitrotyrosine formation and the catalytic activity of cytochrome P450 2B1 Chemical Research in Toxicology. 18: 1203-1210. PMID 16097793 DOI: 10.1021/Tx050100O  1
2005 Bumpus NN, Sridar C, Kent UM, Hollenberg PF. The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 33: 795-802. PMID 15769884 DOI: 10.1124/Dmd.105.003749  1
2005 Blobaum AL, Harris DL, Hollenberg PF. P450 active site architecture and reversibility: inactivation of cytochromes P450 2B4 and 2B4 T302A by tert-butyl acetylenes. Biochemistry. 44: 3831-44. PMID 15751959 DOI: 10.1021/Bi0478953  1
2005 Lin HL, Kent UM, Hollenberg PF. The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. The Journal of Pharmacology and Experimental Therapeutics. 313: 154-64. PMID 15608076 DOI: 10.1124/Jpet.104.079608  0.64
2005 von Weymarn LB, Zhang QY, Ding X, Hollenberg PF. Effects of 8-methoxypsoralen on cytochrome P450 2A13. Carcinogenesis. 26: 621-9. PMID 15579482 DOI: 10.1093/Carcin/Bgh348  0.4
2004 Goosen TC, Cillié D, Bailey DG, Yu C, He K, Hollenberg PF, Woster PM, Cohen L, Williams JA, Rheeders M, Dijkstra HP. Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans. Clinical Pharmacology and Therapeutics. 76: 607-17. PMID 15592332 DOI: 10.1016/J.Clpt.2004.08.019  1
2004 Blobaum AL, Lu Y, Kent UM, Wang S, Hollenberg PF. Formation of a novel reversible cytochrome P450 spectral intermediate: role of threonine 303 in P450 2E1 inactivation. Biochemistry. 43: 11942-52. PMID 15379534 DOI: 10.1021/Bi048882S  1
2004 Lin HL, Kent UM, Zhang H, Waskell L, Hollenberg PF. The functional role of threonine-205 in the mechanism-based inactivation of P450 2B1 by two ethynyl substrates: The importance of the F helix in catalysis Journal of Pharmacology and Experimental Therapeutics. 311: 855-863. PMID 15302894 DOI: 10.1124/Jpet.104.071670  1
2004 Von Weymarn LB, Sridar C, Hollenberg PF. Identification of amino acid residues involved in the inactivation of cytochrome P450 2B1 by two acetylenic compounds: the role of three residues in nonsubstrate recognition Sites. The Journal of Pharmacology and Experimental Therapeutics. 311: 71-9. PMID 15178696 DOI: 10.1124/Jpet.104.069757  0.76
2004 Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 32: 587-94. PMID 15155549 DOI: 10.1124/Dmd.32.6.587  0.76
2004 Harleton E, Webster M, Bumpus NN, Kent UM, Rae JM, Hollenberg PF. Metabolism of N,N',N"-triethylenethiophosphoramide by CYP2B1 and CYP2B6 results in the inactivation of both isoforms by two distinct mechanisms. The Journal of Pharmacology and Experimental Therapeutics. 310: 1011-9. PMID 15121764 DOI: 10.1124/Jpet.104.069112  1
2004 von Weymarn LB, Blobaum AL, Hollenberg PF. The mechanism-based inactivation of p450 2B4 by tert-butyl 1-methyl-2-propynyl ether: structural determination of the adducts to the p450 heme. Archives of Biochemistry and Biophysics. 425: 95-105. PMID 15081898 DOI: 10.1016/J.Abb.2004.03.014  1
2004 Kent UM, Pascual L, Roof RA, Ballou DP, Hollenberg PF. Mechanistic studies with N-benzyl-1-aminobenzotriazole-inactivated CYP2B1: Differential effects on the metabolism of 7-ethoxy-4-(trifluoromethyl)coumarin, testosterone, and benzphetamine Archives of Biochemistry and Biophysics. 423: 277-287. PMID 15001392 DOI: 10.1016/J.Abb.2004.01.007  1
2004 Blobaum AL, Kent UM, Alworth WL, Hollenberg PF. Novel reversible inactivation of cytochrome P450 2E1 T303A by tert-butyl acetylene: the role of threonine 303 in proton delivery to the active site of cytochrome P450 2E1. The Journal of Pharmacology and Experimental Therapeutics. 310: 281-90. PMID 14988423 DOI: 10.1124/Jpet.104.065508  1
2004 Chandrasena RE, Vatsis KP, Coon MJ, Hollenberg PF, Newcomb M. Hydroxylation by the hydroperoxy-iron species in cytochrome P450 enzymes. Journal of the American Chemical Society. 126: 115-26. PMID 14709076 DOI: 10.1021/Ja038237T  1
2003 Reed JR, Hollenberg PF. New perspectives on the conformational equilibrium regulating multi-phasic reduction of cytochrome P450 2B4 by cytochrome P450 reductase. Journal of Inorganic Biochemistry. 97: 276-86. PMID 14511890 DOI: 10.1016/S0162-0134(03)00310-6  1
2003 Reed JR, Hollenberg PF. Examining the mechanism of stimulation of cytochrome P450 by cytochrome b5: the effect of cytochrome b5 on the interaction between cytochrome P450 2B4 and P450 reductase. Journal of Inorganic Biochemistry. 97: 265-75. PMID 14511889 DOI: 10.1016/S0162-0134(03)00275-7  1
2003 Dhaini HR, Thomas DG, Giordano TJ, Johnson TD, Biermann JS, Leu K, Hollenberg PF, Baker LH. Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 2481-5. PMID 12829666 DOI: 10.1200/Jco.2003.06.015  1
2003 Newcomb M, Aebisher D, Shen R, Chandrasena RE, Hollenberg PF, Coon MJ. Kinetic isotope effects implicate two electrophilic oxidants in cytochrome p450-catalyzed hydroxylations. Journal of the American Chemical Society. 125: 6064-5. PMID 12785830 DOI: 10.1021/Ja0343858  1
2003 Lin HL, Zhang H, Waskell L, Hollenberg PF. Threonine-205 in the F helix of P450 2B1 contributes to androgen 16β-hydroxylation activity and mechanism-based inactivation Journal of Pharmacology and Experimental Therapeutics. 306: 744-751. PMID 12721329 DOI: 10.1124/Jpet.103.050260  1
2003 Lin Hl, Kent UM, Zhang H, Waskell L, Hollenberg PF. Mutation of tyrosine 190 to alanine eliminates the inactivation of cytochrome P450 2B1 by peroxynitrite Chemical Research in Toxicology. 16: 129-136. PMID 12588183 DOI: 10.1021/Tx020040B  1
2003 Reed JR, Hollenberg PF. Comparison of substrate metabolism by cytochromes P450 2B1, 2B4, and 2B6: relationship of heme spin state, catalysis, and the effects of cytochrome b5. Journal of Inorganic Biochemistry. 93: 152-60. PMID 12576277 DOI: 10.1016/S0162-0134(02)00597-4  1
2003 Jushchyshyn MI, Kent UM, Hollenberg PF. The mechanism-based inactivation of human cytochrome P450 2B6 by phencyclidine. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 31: 46-52. PMID 12485952 DOI: 10.1124/Dmd.31.1.46  1
2003 Newcomb M, Hollenberg PF, Coon MJ. Multiple mechanisms and multiple oxidants in P450-catalyzed hydroxylations. Archives of Biochemistry and Biophysics. 409: 72-9. PMID 12464246 DOI: 10.1016/S0003-9861(02)00445-9  1
2002 Blobaum AL, Kent UM, Alworth WL, Hollenberg PF. Mechanism-based inactivation of cytochromes P450 2E1 and 2E1 T303A by tert-butyl acetylenes: characterization of reactive intermediate adducts to the heme and apoprotein. Chemical Research in Toxicology. 15: 1561-71. PMID 12482238 DOI: 10.1021/Tx020052X  1
2002 Vuletich JL, Lowe ER, Jianmongkol S, Kamada Y, Kent UM, Bender AT, Demady DR, Hollenberg PF, Osawa Y. Alteration of the heme prosthetic group of neuronal nitric-oxide synthase during inactivation by N(G)-amino-L-arginine in vitro and in vivo. Molecular Pharmacology. 62: 110-8. PMID 12065761 DOI: 10.1124/Mol.62.1.110  1
2002 Newcomb M, Shen R, Lu Y, Coon MJ, Hollenberg PF, Kopp DA, Lippard SJ. Evaluation of norcarane as a probe for radicals in cytochome p450- and soluble methane monooxygenase-catalyzed hydroxylation reactions. Journal of the American Chemical Society. 124: 6879-86. PMID 12059209 DOI: 10.1021/Ja017858O  1
2002 Sridar C, Kent UM, Notley LM, Gillam EM, Hollenberg PF. Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. The Journal of Pharmacology and Experimental Therapeutics. 301: 945-52. PMID 12023523 DOI: 10.1124/Jpet.301.3.945  0.76
2002 Kent UM, Aviram M, Rosenblat M, Hollenberg PF. The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 30: 709-15. PMID 12019199 DOI: 10.1124/Dmd.30.6.709  0.64
2002 Lin HL, Kent UM, Hollenberg PF. Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein. The Journal of Pharmacology and Experimental Therapeutics. 301: 160-7. PMID 11907170 DOI: 10.1124/Jpet.301.1.160  0.64
2002 Kent UM, Mills DE, Rajnarayanan RV, Alworth WL, Hollenberg PF. Effect of 17-alpha-ethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites. The Journal of Pharmacology and Experimental Therapeutics. 300: 549-58. PMID 11805216 DOI: 10.1124/Jpet.300.2.549  1
2001 Kent UM, Jushchyshyn MI, Hollenberg PF. Mechanism-based inactivators as probes of cytochrome P450 structure and function Current Drug Metabolism. 2: 215-243. PMID 11513328 DOI: 10.2174/1389200013338478  1
2001 Moreno RL, Goosen T, Kent UM, Chung FL, Hollenberg PF. Differential effects of naturally occurring isothiocyanates on the activities of cytochrome P450 2E1 and the mutant P450 2E1 T303A. Archives of Biochemistry and Biophysics. 391: 99-110. PMID 11414690 DOI: 10.1006/Abbi.2001.2390  1
2001 Kent UM, Roberts-Kirchhoff ES, Moon N, Dunham WR, Hollenberg PF. Spectral studies of tert-butyl isothiocyanate-inactivated P450 2E1. Biochemistry. 40: 7253-61. PMID 11401573 DOI: 10.1021/Bi0102712  1
2001 Teiber JF, Macé K, Hollenberg PF. Metabolism of the beta-oxidized intermediates of N-nitrosodi-n-propylamine: N-nitroso-beta-hydroxypropylpropylamine and N-nitroso-beta-oxopropylpropylamine. Carcinogenesis. 22: 499-506. PMID 11238192 DOI: 10.1093/Carcin/22.3.499  1
2000 Goosen TC, Kent UM, Brand L, Hollenberg PF. Inactivation of cytochrome P450 2B1 by benzyl isothiocyanate, a chemopreventative agent from cruciferous vegetables. Chemical Research in Toxicology. 13: 1349-59. PMID 11123978 DOI: 10.1021/Tx000133Y  0.64
2000 Teiber JF, Hollenberg PF. Identification of the human liver microsomal cytochrome P450s involved in the metabolism of N-nitrosodi-n-propylamine. Carcinogenesis. 21: 1559-66. PMID 10910959 DOI: 10.1093/Carcin/21.5.559  1
2000 Yanev SG, Kent UM, Roberts ES, Ballou DP, Hollenberg PF. Mechanistic studies of cytochrome P450 2B1 inactivation by xanthates Archives of Biochemistry and Biophysics. 378: 157-166. PMID 10871056 DOI: 10.1006/Abbi.2000.1807  1
2000 Regal KA, Schrag ML, Kent UM, Wienkers LC, Hollenberg PF. Mechanism-based inactivation of cytochrome P450 2B1 by 7-ethynylcoumarin: verification of apo-P450 adduction by electrospray ion trap mass spectrometry. Chemical Research in Toxicology. 13: 262-70. PMID 10775326 DOI: 10.1021/Tx990195S  1
2000 Hanna IH, Reed JR, Guengerich FP, Hollenberg PF. Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver. Archives of Biochemistry and Biophysics. 376: 206-16. PMID 10729207 DOI: 10.1006/Abbi.2000.1708  1
2000 Reed JR, Kraft MD, Hollenberg PF. Rat liver cytosol catalyzes a reaction involving activated N-nitrosodimethylamine and a carbohydrate from the pentose phosphate pathway. Chemical Research in Toxicology. 13: 126-33. PMID 10688537 DOI: 10.1021/Tx990151J  1
2000 Newcomb M, Shen R, Choi SY, Toy PH, Hollenberg PF, Vaz ADN, Coon MJ. Cytochrome P450-catalyzed hydroxylation of mechanistic probes that distinguish between radicals and cations. Evidence for cationic but not for radical intermediates Journal of the American Chemical Society. 122: 2677-2686. DOI: 10.1021/Ja994106+  1
1999 Moreno RL, Kent UM, Hodge K, Hollenberg PF. Inactivation of cytochrome P450 2E1 by benzyl isothiocyanate. Chemical Research in Toxicology. 12: 582-7. PMID 10409397 DOI: 10.1021/Tx9900019  1
1998 Roberts ES, Lin Hl, Crowley JR, Vuletich JL, Osawa Y, Hollenberg PF. Peroxynitrite-mediated nitration of tyrosine and inactivation of the catalytic activity of cytochrome P450 2B1. Chemical Research in Toxicology. 11: 1067-74. PMID 9760281 DOI: 10.1021/Tx980099B  1
1998 Roberts ES, Alworth WL, Hollenberg PF. Mechanism-based inactivation of cytochromes P450 2E1 and 2B1 by 5-phenyl-1-pentyne. Archives of Biochemistry and Biophysics. 354: 295-302. PMID 9637739 DOI: 10.1006/Abbi.1998.0679  1
1998 He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chemical Research in Toxicology. 11: 252-9. PMID 9548795 DOI: 10.1021/Tx970192K  1
1998 Hanna IH, Teiber JF, Kokones KL, Hollenberg PF. Role of the alanine at position 363 of cytochrome P450 2B2 in influencing the NADPH- and hydroperoxide-supported activities. Archives of Biochemistry and Biophysics. 350: 324-32. PMID 9473308 DOI: 10.1006/Abbi.1997.0534  1
1997 Kent UM, Bend JR, Chamberlin BA, Gage DA, Hollenberg PF. Mechanism-based inactivation of cytochrome P450 2B1 by N-benzyl-1-aminobenzotriazole. Chemical Research in Toxicology. 10: 600-8. PMID 9168259 DOI: 10.1021/Tx960184O  1
1997 Shu L, Hollenberg PF. Alkylation of cellular macromolecules and target specificity of carcinogenic nitrosodialkylamines: Metabolic activation by cytochromes P450 2B1 and 2E1 Carcinogenesis. 18: 801-810. PMID 9111218 DOI: 10.1093/Carcin/18.4.801  1
1997 Bellevue FH, Woster PM, Edwards DJ, He K, Hollenberg PF. Synthesis and biological evaluation of 6',7'-dihydroxybergamottin (6,7-DHB, a naturally occurring inhibitor of cytochrome P450 3A4 Bioorganic and Medicinal Chemistry Letters. 7: 2593-2598. DOI: 10.1016/S0960-894X(97)10043-9  1
1996 Beebe LE, Roberts ES, Fornwald LW, Hollenberg PF, Alworth WL. Mechanism-based inhibition of mouse P4502b-10 by selected arylalkynes. Biochemical Pharmacology. 52: 1507-13. PMID 8937464 DOI: 10.1016/S0006-2952(96)00525-4  1
1996 Roberts ES, Pernecky SJ, Alworth WL, Hollenberg PF. A role for threonine 302 in the mechanism-based inactivation of P450 2B4 by 2-ethynylnaphthalene. Archives of Biochemistry and Biophysics. 331: 170-6. PMID 8660695 DOI: 10.1006/Abbi.1996.0295  1
1996 Shu L, Hollenberg PF. Role of cytochrome P450 in DNA damage induced by N-nitrosodialkylamines in cultured rat hepatocytes Carcinogenesis. 17: 569-576. PMID 8631147 DOI: 10.1093/carcin/17.3.569  1
1996 Shu L, Hollenberg PF. Identification of the cytochrome p450 isozymes involved in the metabolism of N-nitrosodipropyl-, N-nitrosodibutyl- and N-nitroso-n-butyl-n-propylamine Carcinogenesis. 17: 839-848. PMID 8625499 DOI: 10.1093/carcin/17.4.839  1
1996 Choi SY, Eaton PE, Hollenberg PF, Liu KE, Lippard SJ, Newcomb M, Putt DA, Upadhyaya SP, Xiong Y. Regiochemical variations in reactions of methylcubane with tert-butoxyl radical, cytochrome P-450 enzymes, and a methane monooxygenase system Journal of the American Chemical Society. 118: 6547-6555. DOI: 10.1021/Ja952226L  1
1995 Putt DA, Ding X, Coon MJ, Hollenberg PF. Metabolism of aflatoxin B1 by rabbit and rat nasal mucosa microsomes and purified cytochrome P450, including isoforms 2A10 and 2A11. Carcinogenesis. 16: 1411-7. PMID 7788862 DOI: 10.1093/Carcin/16.6.1411  1
1995 Roberts ES, Ballou DP, Hopkins NE, Alworth WL, Hollenberg PF. Mechanistic studies of 9-ethynylphenanthrene-inactivated cytochrome P450 2B1. Archives of Biochemistry and Biophysics. 323: 303-12. PMID 7487092 DOI: 10.1006/Abbi.1995.9960  1
1995 Roberts ES, Hopkins NE, Zaluzec EJ, Gage DA, Alworth WL, Hollenberg PF. Mechanism-based inactivation of cytochrome P450 2B1 by 9-ethynylphenanthrene. Archives of Biochemistry and Biophysics. 323: 295-302. PMID 7487091 DOI: 10.1006/Abbi.1995.9961  1
1994 Roberts ES, Hopkins NE, Zaluzec EJ, Gage DA, Alworth WL, Hollenberg PF. Identification of active-site peptides from 3H-labeled 2-ethynylnaphthalene-inactivated P450 2B1 and 2B4 using amino acid sequencing and mass spectrometry. Biochemistry. 33: 3766-71. PMID 8142377 DOI: 10.1021/Bi00178A037  0.56
1994 Atkinson JK, Hollenberg PF, Ingold KU, Johnson CC, Le Tadic MH, Newcomb M, Putt DA. Cytochrome P450-catalyzed hydroxylation of hydrocarbons: kinetic deuterium isotope effects for the hydroxylation of an ultrafast radical clock. Biochemistry. 33: 10630-7. PMID 8075063 DOI: 10.1021/bi00201a009  0.48
1993 Roberts ES, Hopkins NE, Alworth WL, Hollenberg PF. Mechanism-based inactivation of cytochrome P450 2B1 by 2-ethynylnaphthalene: identification of an active-site peptide. Chemical Research in Toxicology. 6: 470-9. PMID 8374044 DOI: 10.1021/Tx00034A013  1
1987 Kokkinakis DM, Wieboldt R, Hollenberg PF, Scarpelli DG. Structural relationships of pancreatic nitrosamine carcinogens. Carcinogenesis. 8: 81-90. PMID 3802397 DOI: 10.1093/Carcin/8.1.81  1
1980 Reddy MK, Hollenberg PF, Reddy JK. Partial purification and immunoreactivity of an 80,000-molecular-weight polypeptide associated with peroxisome proliferation in rat liver Biochemical Journal. 188: 731-740. PMID 6781475 DOI: 10.1042/Bj1880731  1
1975 Hager LP, Hollenberg PF, Rand-Meir T, Chiang R, Doubek D. Chemistry of peroxidase intermediates. Annals of the New York Academy of Sciences. 244: 80-93. PMID 1056179 DOI: 10.1111/J.1749-6632.1975.Tb41524.X  1
1973 Champion PM, Münck E, Debrunner PG, Hollenberg PF, Hager LP. Mössbauer investigations of chloroperoxidase and its halide complexes. Biochemistry. 12: 426-35. PMID 4734232  1
1972 Czerwinski EW, Mathews FS, Hollenberg P, Drickamer K, Hager LP. Crystallographic study of cytochrome b 562 from Escherichia coli. Journal of Molecular Biology. 71: 819-21. PMID 4567475 DOI: 10.1016/S0022-2836(72)80046-9  1
1965 Wheeler KP, Inui Y, Hollenberg PF, Eavenson E, Christensen HN. Relation of amino acid transport to sodium-ion concentration Bba - Biophysics Including Photosynthesis. 109: 620-622. PMID 5867563 DOI: 10.1016/0926-6585(65)90191-3  1
Show low-probability matches.